ORIGINAL ARTICLE
The clinicopathological significance of METTL3/SERPINE2 immunoexpression in urothelial carcinoma of the urinary bladder
1
Department of Pathology, Faculty of Medicine, Minia University, El-Minia, Egypt
These authors had equal contribution to this work
Submission date: 2026-01-28
Final revision date: 2026-03-14
Acceptance date: 2026-03-24
Publication date: 2026-06-08
Corresponding author
Hany Yousry Sayed
Department of Pathology, Faculty of Medicine, Minia University 61511, El-Minia, Egypt
Department of Pathology, Faculty of Medicine, Minia University 61511, El-Minia, Egypt
Pol J Pathol 2026;77(1):53-61
KEYWORDS
TOPICS
ABSTRACT
The aim of this study was to investigate the immunohistochemical expression of METTL3 and SERPINE2 in urothelial carcinoma and to assess their individual and combined associations with clinicopathological features and possible correlation.
This study included 126 cases of urothelial carcinoma. Immunohistochemical staining was used to evaluate METTL3 and SERPINE2 expression in tumour tissues. Clinico- pathological data including age, sex, bilharziasis, tumour grade and stage, lymph node status, lymphovascular invasion, soft tissue surgical margins, and tumour- infiltrating lymphocytes (TIL) were collected. Statistical analysis was performed to determine associations between marker expression and clinicopathological parameters.
High nuclear METTL3 expression was significantly associated with a higher tumour grade, advanced stage, increased TIL, and lymphovascular invasion, with no significant association with age, sex, bilharziasis, nodal stage, or surgical margins. High cytoplasmic SERPINE2 expression was significantly associated with an advanced stage, lymph node metastasis, and positive soft tissue margins, while no association was found with age, sex, bilharziasis, grade, TIL, or lymphovascular invasion. Combined high METTL3/high SERPINE2 expression correlated significantly with a high grade, advanced tumour and nodal stages, low TIL, and positive surgical margins, indicating a more aggressive tumour phenotype.
METTL3 and SERPINE2 are associated with adverse pathological features in urothelial carcinoma, and their combined overexpression may serve as a potential prognostic biomarker.
REFERENCES (22)
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 135.
2.
Koch J, Neuberger M, Schmidt-Dengler M, Xu J, Carneiro VC, Ellinger J, et al. Reinvestigating the clinical relevance of the m6A writer METTL3 in urothelial carcinoma of the bladder. iScience 2023; 26: 107300.
3.
Wen D, Fu P, Shuai G, Wang Y, Yu S, Liu H, et al. The impact of METTL3 on bladder cancer through m6A modification: a potential therapeutic target and prognostic biomarker. Front Oncol 2025; 15: 1622117.
4.
Chuang HW, Hsia KT, Liao JB, Yeh CC, Kuo WT, Yang YF. SERPINE2 overexpression is associated with poor prognosis of urothelial carcinoma. Diagnostics (Basel) 2021; 11: 1928.
5.
Guo CC, Shen SS, Czerniak B. Recent advances in the classification of bladder cancerupdates from the 5th edition of the World Health Organization classification of the urinary and male genital tumors. Bladder Cancer 2023; 9: 14.
6.
Moch H, Amin MB, Berney DM, Compérat EM, Gill AJ, Hartmann A, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organspart A: renal, penile, and testicular tumours. Eur Urol 2022; 82: 458468.
7.
Drachneris J, Rasmusson A, Morkunas M, Fabijonavicius M, Cekauskas A, Jankevicius F, et al. CD8+ cell density gradient across the tumor epitheliumstromal interface of non-muscle invasive papillary urothelial carcinoma predicts recurrence-free survival after BCG immunotherapy. Cancers (Basel) 2023; 15: 1205.
8.
Yaprak Bayrak B, Dogan HN, Teke K, Yuvak H, Dillioglu- gil O. The role of tumor-infiltrating lymphocytes and depth of invasion in T1 bladder cancer: a retrospective analysis. BMC Urol 2025; 25: 135.
9.
Xu QC, Tien YC, Shi YH, Chen S, Zhu YQ, Huang XT, et al. METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m6A-YTHDF2- dependent manner. Oncogene 2022; 41: 16221633.
10.
Zou G, Lv Y, Kong M, Xiang B, Chen J. Upregulation of SERPINE2 results in poor prognosis of hepatoblastoma via promoting invasion abilities. Dis Markers 2022; 2022: 2283541.
11.
International Agency for Research on Cancer (IARC). Bladder cancer fact sheet. GLOBOCAN 2022. Available from: https://gco.iarc.who.int/fact-... (accessed: 13.01. 2026).
12.
Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H, Wu M, et al. The m6A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-B/MYC signaling network. Oncogene 2019; 38: 36673680.
13.
Liu CH, Zhang JJ, Zhang QJ, Dong Y, Shi ZD, Hong SH, et al. METTL3 regulates the proliferation, metastasis and EMT progression of bladder cancer through P3H4. Cell Signal 2024; 113: 110971.
14.
Yue B, Song C, Yang L, Cui R, Cheng X, Zhang Z, et al. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Mol Cancer 2019; 18: 142.
15.
Zhao C, Ling X, Xia Y, Yan B, Guan Q. The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis. Cancer Cell Int 2021; 21: 441.
16.
Liu L, Wu Y, Li Q, Liang J, He Q, Zhao L, et al. METTL3 promotes tumorigenesis and metastasis through BMI1 m6A methylation in oral squamous cell carcinoma. Mol Ther 2020; 28: 21772190.
17.
Li Y, He X, Lu X, Gong Z, Li Q, Zhang L, et al. METTL3 acetylation impedes cancer metastasis via fine-tuning its nuclear and cytosolic functions. Nat Commun 2022; 13: 6350.
18.
Liu Y, Li X, Chen S, Zhu C, Shi Y, Dang S, et al. Pan-cancer analysis of SERPINE family genes as biomarkers of cancer prognosis and response to therapy. Front Mol Biosci 2024; 10: 1277508.
19.
Shen Y, Wang X, Xu J, Lu L. SERPINE2, a poor biomarker of endometrial cancer, promotes the proliferation and mobility of EC cells. Cancer Biomark 2017; 19: 271278.
20.
Mazzoccoli G, Pazienza V, Panza A, Valvano MR, Benegiamo G, Vinciguerra M, et al. ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer. J Cancer Res Clin Oncol 2012; 138: 501511.
21.
Sasahira T, Kurihara-Shimomura M, Shimomura H, Kirita T. SERPINE2 is an oral cancer-promoting factor that induces angiogenesis and lymphangiogenesis. Int J Clin Oncol 2021; 26: 18311839.
22.
Yan T, Wang Q, Liu Y. METTL3 stabilizes SERPINE2 via the m6A modification to drive the malignant progression of gastric signet ring cell carcinoma. Transl Cancer Res 2025; 14: 78.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
